Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -376.33% is 26% above its 4-year average of -510.18%, around the middle of its 4-year range (-1534.74%–567.73%).
29.15% above its 12-month average of -531.17%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1267.06%.
EBITDA MARGIN
-376.33%
EBITDA MARGIN AVG TTM
-531.17%
EBITDA MARGIN AVG 3Y
-392.49%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+29.15%
CURRENT VS 3Y AVG
+4.12%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Nano-X Imaging Ltd.
Market Cap
$42.81M
EBITDA Margin
-376.33%
TTM Avg
-531.17%
3Y Avg
-392.49%
5Y Avg
N/A
Market Cap
$42.46M
EBITDA Margin
-0.99%
TTM Avg
4.72%
3Y Avg
-25.09%
5Y Avg
-32.37%
Market Cap
$43.52M
EBITDA Margin
-89.16%
TTM Avg
-101.97%
3Y Avg
-124.94%
5Y Avg
-147.77%
Market Cap
$43.63M
EBITDA Margin
-131.42%
TTM Avg
-148.69%
3Y Avg
-221.80%
5Y Avg
-210.76%
Market Cap
$45.07M
EBITDA Margin
-3807.96%
TTM Avg
-2001.11%
3Y Avg
-1442.90%
5Y Avg
-1442.90%
Market Cap
$44.89M
EBITDA Margin
14.14%
TTM Avg
17.13%
3Y Avg
-2.79%
5Y Avg
-117.76%
Market Cap
$45.05M
EBITDA Margin
-148.02%
TTM Avg
-167.05%
3Y Avg
-193.51%
5Y Avg
-252.90%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nano-X Imaging Ltd. (NNOX) | $42.81M | -376.33% | -531.17% | -392.49% | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $42.46M | -0.99% | 4.72% | -25.09% | -32.37% |
| CVRx, Inc. (CVRX)vs › | $43.52M | -89.16% | -101.97% | -124.94% | -147.77% |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $43.63M | -131.42% | -148.69% | -221.80% | -210.76% |
| Precipio, Inc. (PRPO)vs › | $41.95M | 2.29% | -7.32% | -44.00% | -66.61% |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.07M | -3807.96% | -2001.11% | -1442.90% | -1442.90% |
| SANUWAVE Health Inc. (SNWV)vs › | $44.89M | 14.14% | 17.13% | -2.79% | -117.76% |
| DarioHealth Corp. (DRIO)vs › | $45.05M | -148.02% | -167.05% | -193.51% | -252.90% |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.53M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $45.16M | -203.44% | -129.78% | -288.25% | -438.27% |
Gross Margin
-98.2%
EBITDA Margin
-376.3%
Operating Margin
-466.2%
Net Margin
-747.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1267.06% |
| 2026-03-31 | -277.68% |
| 2025-12-31 | -404.30% |
| 2025-09-30 | -327.15% |
| 2025-06-30 | -379.67% |
| 2025-03-31 | -395.99% |
| 2024-12-31 | -401.33% |
| 2024-09-30 | -369.78% |
| 2024-06-30 | -429.01% |
| 2024-03-31 | -397.38% |
| 2023-12-31 | -427.83% |
| 2023-09-30 | -770.31% |
| 2023-06-30 | -578.00% |
| 2023-03-31 | -374.74% |
| 2022-12-31 | 567.73% |
| 2022-09-30 | -695.41% |
| 2022-06-30 | -878.77% |
| 2022-03-31 | -1055.48% |
| 2021-12-31 | -1534.74% |
